Patients n | 18 | 18 | |
Patient characteristics | | | |
Age years | 61 (56–65) | 68 (54–76) | 0.37 |
Male sex | 12 (67%) | 14 (78%) | 0.71 |
Body mass index kg·m−2 | 31 (27–36) | 27 (24–36) | 0.83 |
SAPS II at admission | 48 (34–56) | 49 (38–65) | 0.14 |
Length of ICU stay days¶,+ | 10 (5–14) | 13 (8–19) | 0.29 |
Duration of MV days+ | 9 (4–14) | 13 (7–18) | 0.33 |
Number of days with sedation+ | 5 (3–11) | 8 (5–14) | 0.44 |
Cumulative dose of midazolam mg¶,+ | 528 (264–1848) | 1308 (498–2796) | 0.21 |
Respiratory parameters at time of PSG | | | |
Maximal inspiratory pressure cmH2O | 41 (33–53) | 41 (34–57) | 0.97 |
P0.1 cmH2O | 3.6 (3.4–3.8) | 3.6 (3.4–3.8) | 0.51 |
pH | 7.43 (7.40–7.47) | 7.43 (7.41–7.48) | 0.68 |
Bicarbonates level mmol·L−1 | 32 (28–35) | 27 (25–34) | 0.27 |
PCO2 mmHg | 48 (43–56) | 42 (40–47) | 0.19 |
PaO2/FIO2 mmHg | 203 (186–238) | 217 (179–252) | 0.70 |
Clinical parameters at time of PSG | | | |
SOFA score | 3 (2–4) | 3 (3–4) | 0.60 |
RASS score | 0 (0–0) | 0 (−0.8–0) | 0.34 |
ICDSC score | 1 (0–3) | 3 (1–4) | 0.13 |
Delirium | 4 (22%) | 8 (44%) | 0.29 |
MRC score | 55 (43–60) | 34 (25–57) | 0.11 |
ICU-acquired weakness§ | 6 (33%) | 11 (61%) | 0.18 |
Outcomes | | | |
Duration of MV after PSG days | 2 (1–2) | 4 (2–8) | 0.01 |
Prolonged weaning of >48 h | 2 (11%) | 12 (67%) | 0.002 |